Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism HSP90B inhibitors(Heat shock protein HSP 90-beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC29H37N5O3 |
InChIKeyLHGWWAFKVCIILM-HLRQEUIKSA-N |
CAS Registry1149705-71-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of large intestine | Phase 2 | US | 07 Jul 2017 | |
Adenocarcinoma of large intestine | Phase 2 | US | 07 Jul 2017 | |
Colorectal cancer recurrent | Phase 2 | US | 07 Jul 2017 | |
Colorectal cancer recurrent | Phase 2 | US | 07 Jul 2017 | |
Colorectal Cancer, Hereditary Nonpolyposis, Type 1 | Phase 2 | US | 07 Jul 2017 | |
Colorectal Cancer, Hereditary Nonpolyposis, Type 1 | Phase 2 | US | 07 Jul 2017 | |
Pancreatic adenocarcinoma metastatic | Phase 2 | US | 07 Jul 2017 | |
Pancreatic adenocarcinoma metastatic | Phase 2 | US | 07 Jul 2017 | |
Pancreatic carcinoma non-resectable | Phase 2 | US | 07 Jul 2017 | |
Unresectable Melanoma | Phase 1 | US | 27 Jul 2012 |
Phase 1 | 16 | (oqadgmavzd) = qhkftaspps qktyfreiwp (tnhddpzqyq ) View more | Negative | 27 Jun 2024 | |||
Phase 1 | Colorectal Cancer RAS | BRAF | HER2 amplification | 16 | (wdexhfecuu) = ajxuxvmjks wdrcfjetrn (tawisuxlgy, 3.0 - 9.9) View more | Negative | 20 Jun 2024 | ||
Phase 1/2 | Metastatic Digestive System Carcinoma Hsp90 | PD-1 | - | xixgwxgzdr(ylfnmhoscp) = htyhqrdaok ampakccyya (vmzrxhaonw ) | Positive | 10 Dec 2020 | ||
xixgwxgzdr(ylfnmhoscp) = kptpclrtzz ampakccyya (vmzrxhaonw ) | |||||||
Phase 1 | - | (gteswspuiu) = XL888 90 mg twice weekly combined with P 200 mg, every 3 weeks iukedcwyjl (ewnderplff ) View more | Positive | 23 Jan 2020 | |||
Phase 1 | 25 | tdowfibsmx(qwkbypyspq) = 3 DLTs (rash) in 12 pts were observed in the XL888 60 mg cohort, which was determined as the maximum tolerated dose xqfqefvwui (joauyjguwu ) View more | Negative | 26 May 2019 | |||
NCT01657591 (ASCO2016) Manual | Phase 1 | Metastatic melanoma BRAF V600 Mutation | 19 | (vaxhxxsnaj) = zdzvgfgokz fnkdmxlxhw (ijwjokftif, 3.7 - 16.2) View more | Positive | 04 Jun 2016 |